Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Legend Biotech ( (LEGN) ) just unveiled an update.
On January 22, 2025, Legend Biotech announced preliminary sales figures for CARVYKTI® for the quarter ending December 31, 2024, reporting approximately $334 million in net trade sales. The sales data, provided by Janssen Biotech, Inc., is yet to be independently verified and awaits the completion of Legend Biotech’s financial statements for the period, highlighting potential impacts on the company’s revenue recognition and market positioning.
More about Legend Biotech
Legend Biotech Corporation is a company operating in the biotechnology industry, focusing on the development of innovative cellular therapies. It collaborates with Janssen Biotech, Inc., and is involved in producing CARVYKTI®, a treatment aimed at addressing unmet medical needs in the field of oncology.
YTD Price Performance: -0.17%
Average Trading Volume: 1,471,691
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $6.36B
See more insights into LEGN stock on TipRanks’ Stock Analysis page.
